Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
New Biofermin S Plus Tablets
- Development stage
- Unknown
- Lead developer
- Biofermin Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
New Biofermin S Plus Tablets is a probiotic combination product developed by Biofermin Pharmaceutical Co., Ltd. (a subsidiary of Taisho Pharmaceutical). It is an enhanced version of the classic 'New Biofermin S' formulation, designed to regulate the intestinal flora and improve gastrointestinal symptoms such as constipation, loose stools, and abdominal bloating. The 'Plus' formulation contains four distinct strains of lactic acid bacteria and bifidobacteria: *Bifidobacterium bifidum*, *Bifidobacterium longum*, *Enterococcus faecalis*, and *Lactobacillus acidophilus*. These strains work synergistically throughout the small and large intestines to restore microbial balance, produce organic acids (like lactic and acetic acid), and inhibit the growth of harmful bacteria. The product is marketed in Japan as a Designated Quasi-drug for intestinal regulation.
- Brand names
- New Biofermin S Plus TabletsShin Biofermin S Plus
- Other names
- Shin Biofermin S Plus Tablets
Beyond the preview
Go deeper on New Biofermin S Plus Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New Biofermin S Plus Tablets.